Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Mayo Clinic
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Baylor College of Medicine
National Cancer Institute, Egypt
H. Lee Moffitt Cancer Center and Research Institute
Baylor College of Medicine
Immatics US, Inc.
Acepodia Biotech, Inc.
West China Hospital
SCG Cell Therapy Pte. Ltd.
HRYZ Biotech Co.
Brooklyn ImmunoTherapeutics, LLC
Dana-Farber Cancer Institute
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
The Affiliated Hospital of Xuzhou Medical University
The Affiliated Hospital of Xuzhou Medical University
CEL-SCI Corporation
Genocea Biosciences, Inc.
Corregene Biotechnology Co., Ltd
Gliknik Inc.
Mie University
Brooklyn ImmunoTherapeutics, LLC
Fujian Cancer Hospital
Gruppo Oncologico del Nord-Ovest
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mie University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
National Health Research Institutes, Taiwan
National Cancer Institute (NCI)
Herlev Hospital